Sei Investments Co. Buys 591,495 Shares of Niagen Bioscience, Inc. $NAGE

Sei Investments Co. boosted its stake in shares of Niagen Bioscience, Inc. (NASDAQ:NAGE) by 155.6% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 971,574 shares of the company’s stock after purchasing an additional 591,495 shares during the period. Sei Investments Co.’s holdings in Niagen Bioscience were worth $4,285,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of NAGE. Dimensional Fund Advisors LP raised its stake in shares of Niagen Bioscience by 16.4% in the first quarter. Dimensional Fund Advisors LP now owns 1,071,133 shares of the company’s stock worth $4,723,000 after buying an additional 150,763 shares during the period. SteelPeak Wealth LLC purchased a new stake in Niagen Bioscience in the 1st quarter worth approximately $14,875,000. Chicago Partners Investment Group LLC purchased a new stake in Niagen Bioscience in the 1st quarter worth approximately $214,000. OP Asset Management Ltd bought a new stake in Niagen Bioscience during the 1st quarter worth approximately $1,475,000. Finally, Silverberg Bernstein Capital Management LLC raised its stake in Niagen Bioscience by 5.3% during the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 138,102 shares of the company’s stock worth $609,000 after acquiring an additional 6,940 shares during the period. Institutional investors own 15.41% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on NAGE shares. Roth Capital reiterated a “buy” rating on shares of Niagen Bioscience in a research report on Wednesday. Canaccord Genuity Group decreased their price objective on shares of Niagen Bioscience from $13.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, May 5th. Freedom Capital upgraded shares of Niagen Bioscience to a “strong-buy” rating in a research note on Monday, July 6th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Niagen Bioscience in a report on Friday, July 17th. Finally, HC Wainwright reiterated a “buy” rating on shares of Niagen Bioscience in a research note on Wednesday, July 1st. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, Niagen Bioscience currently has a consensus rating of “Buy” and an average price target of $10.33.

Niagen Bioscience Trading Down 14.7%

NASDAQ:NAGE opened at $2.96 on Thursday. The business’s 50-day moving average is $3.41 and its 200 day moving average is $4.34. Niagen Bioscience, Inc. has a 12 month low of $2.87 and a 12 month high of $11.29. The company has a market capitalization of $235.73 million, a P/E ratio of 16.45 and a beta of 2.09.

Niagen Bioscience (NASDAQ:NAGE) last released its quarterly earnings results on Tuesday, August 4th. The company reported $0.01 earnings per share for the quarter, meeting the consensus estimate of $0.01. Niagen Bioscience had a return on equity of 18.31% and a net margin of 12.39%.The business had revenue of $29.78 million during the quarter, compared to analysts’ expectations of $29.95 million. On average, research analysts forecast that Niagen Bioscience, Inc. will post 0.21 earnings per share for the current year.

Niagen Bioscience Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.